PlayOn11 - Where Fans Become Winners
Revolution beats expectations | ApexOnco - Clinical Trials news and analysis

Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic canc...

BUSINESS NEWS April 13, 2026

Revolution beats expectations | ApexOnco - Clinical Trials news and analysis

Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic cancer, but it's already calling the results transformative.

1 views 0 likes 0 comments
Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic cancer, but it's already calling the results transformative.

Author: Oncology Pipeline

Read Original Article

Related News

Top Categories